RESEARCH · RETATRUTIDE · PHARMACOKINETICS
Retatrutide Pharmacokinetics: Half-Life, Exposure and Dose–Response in Phase 1–2 Studies
Retatrutide (LY3437943) is a single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors. Our earlier articles cover the clinical trial programme and the glucagon-receptor, energy-expenditure and liver research. This article looks at the layer underneath both: how long the molecule stays in circulation, how exposure scales across the levels tested, and how the published Phase 1 and 2 studies describe the relationship between regimen and response. PurixLab’s Retatrutide 10mg is a research material for laboratory research use only; nothing here is dosing guidance, and clinical formulations are not the same as a research vial.
Designed for a long half-life
The discovery paper describes LY3437943 as a 39-amino-acid peptide engineered from a GIP backbone, with α-aminoisobutyric acid at position 2 for stability against DPP-4 cleavage and a C20 fatty diacid attached through a linker to lysine 17, so that the peptide binds albumin reversibly as a half-life-extension strategy [1]. The approach follows earlier incretin chemistry. In the semaglutide programme, the fatty-acid moiety and linker were the key features securing high albumin affinity and prolonged exposure, with a plasma half-life of 46.1 h after intravenous administration in mini-pigs [2]. The dual GIP/GLP-1 agonist tirzepatide (LY3298176) was likewise a fatty-acid-modified peptide designed for once-weekly subcutaneous administration [3].
Single ascending doses: about six days
In the first-in-human single-ascending-dose study reported in the same paper, healthy participants reached maximum plasma concentrations 12-72 h after administration, the mean half-life was approximately 6 days, and exposure appeared nearly dose-proportional across the range studied. Between-participant variability was moderate, with geometric CV% of 13-34% for AUC [1]. The pharmacodynamic signal outlasted a single administration: a reduction in body weight persisted up to day 43 [1].
Multiple ascending doses in type 2 diabetes
The Phase 1b multiple-ascending-dose trial enrolled 72 adults with type 2 diabetes in five cohorts over 12 weeks, with the two highest cohorts reached through stepwise escalation. Pharmacokinetics were dose proportional and the half-life was approximately 6 days [4]. Pharmacodynamic readouts tracked exposure: placebo-adjusted mean daily plasma glucose fell significantly only in the three highest cohorts, and placebo-adjusted body-weight reduction appeared dose dependent, reaching -8.96 kg in the top escalation cohort [4]. Gastrointestinal disorders were the most frequent adverse events, and 29 participants discontinued early, a reminder that small Phase 1 cohorts give imprecise estimates [4].
Phase 2: shaping the dose–response curve
The Phase 2 obesity trial was designed because dose-response relationships for side effects, safety and efficacy were not known. It randomised 338 adults to placebo or one of several once-weekly maintenance levels, some reached from different starting steps, for 48 weeks [5]. Mean weight change at 24 weeks was -7.2% at the lowest level, -12.9% and -17.3% in the two combined middle groups and -17.5% at the highest level, versus -1.6% with placebo; at 48 weeks the figures were -8.7%, -17.1%, -22.8% and -24.2%, versus -2.1% [5]. The curve is steep at the low end and flattens between the two highest levels. Gastrointestinal events were dose-related and partially mitigated by a lower starting step, and dose-dependent heart-rate increases peaked at 24 weeks and declined thereafter [5].
The companion Phase 2 trial in type 2 diabetes randomised 281 participants to placebo, dulaglutide or six retatrutide arms with different escalation schemes. At 36 weeks, body weight decreased dose dependently, from 3.19% in the lowest arm to 16.94% in the highest, while slow- and fast-escalation arms with the same maintenance level reached 16.81% and 16.34%. Gastrointestinal events ranged from 13% in the lowest arm to 50% in a fast-escalation arm [6]. The authors state that these data informed selection for the Phase 3 programme [6], and the Phase 3 TRANSCEND-T2D-1 monotherapy trial then reported graded weight changes of -11.5%, -13.9% and -15.3% across its three maintenance levels, versus -2.6% with placebo at 40 weeks [7].
Modelling across trials
Model-based meta-analyses (MBMA) pool published trial results to fit time-course and dose-response curves. One MBMA of fifty-five placebo-controlled trials with 16,269 participants and 12 GLP-1-based drugs found significant dose-response relationships for six drugs, a maximum modelled weight-reduction effect ranging from 4.25 kg for liraglutide to 22.6 kg for retatrutide, and 52-week effects of 7.03 kg, 11.07 kg and 24.15 kg for mono-, dual- and tri-agonists [8]. A larger MBMA of 137 trials (310 treatment arms, 56,683 patients) used five longitudinal models and placed retatrutide first for weight change, but with a wide 95% confidence interval (-43.89% to -3.01%) reflecting how few retatrutide arms existed [9]. These analyses use summary data. In a PubMed search in October 2026 we did not find a peer-reviewed population-PK or individual-level exposure–response model for retatrutide.
Measuring retatrutide in biological samples
PK work depends on assays. An LC-HRMS method validated to anti-doping criteria reported limits of detection of 6.14 ng/mL in plasma and 2.44 ng/mL in urine. In samples from four people who had used the compound, neither intact retatrutide nor metabolite signals were detected in urine; plasma profiles were nonmonotonic, consistent with prolonged subcutaneous absorption and depot-like release, and plasma detection extended to approximately 56 days after the first administration [10]. A multiplexed LC-HRMS method for nine GLP-1-class peptides, including retatrutide, combined accurate-mass full scans with data-dependent fragmentation and reported LODs of 0.44-2.06 ng/mL [11]. The same kind of method is how laboratories confirm the identity of a reference material.
Biomarkers as exposure readouts
Post hoc metabolomics from both Phase 2 trials found that higher doses were associated with changes in a cluster of fatty-acid-oxidation metabolites, including 3-hydroxybutyrate, acetylcarnitine, free carnitine and long-chain acylcarnitines. Mediation analyses suggested these changes mediated 23.2% of the weight-reduction response in participants without type 2 diabetes and 12.7% in those with it [12]. Such markers may eventually link exposure to mechanism, but they come from exploratory analyses.
What remains open
- Small PK datasets. Half-life estimates come from single- and multiple-ascending-dose Phase 1 cohorts [1,4].
- Plateau or not. Weight curves flatten between the highest Phase 2 levels, but the trials were not designed to define a maximum [5,6].
- Escalation shapes response. Starting step and escalation speed changed tolerability, so the regimen, not only the level, matters [5,6].
- Special populations. Reviews summarise efficacy and safety rather than PK covariates such as renal or hepatic function [13].
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. PubMed 26308095 · doi:10.1021/acs.jmedchem.5b00726
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PubMed 30473097 · PMC6308032 · doi:10.1016/j.molmet.2018.09.009
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040 · doi:10.1016/S0140-6736(22)02033-5
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PubMed 42250575 · doi:10.1016/S0140-6736(26)00967-0
- Guo H, Yang J, Huang J, et al. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials. Obes Pillars. 2025;13:100162. PubMed 39980735 · PMC11840199 · doi:10.1016/j.obpill.2025.100162
- Zhang S, Yu B, Xu J, et al. Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis. Diabetes Technol Ther. 2025;27(6):422-429. PubMed 39911047 · doi:10.1089/dia.2024.0533
- Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, et al. Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis. Rapid Commun Mass Spectrom. 2026;40(23):e70179. PubMed 42745421 · PMC13578828 · doi:10.1002/rcm.70179
- Tong LH, Leung KK, Hung CT. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application. J Chromatogr A. 2026;1786:467288. PubMed 42603384 · doi:10.1016/j.chroma.2026.467288
- Pearson MJ, Willency JA, Lin Y, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026:dgag201. PubMed 42135195 · doi:10.1210/clinem/dgag201
- Panou T, Gouveri E, Popovic DS, et al. Retatrutide in type 2 diabetes mellitus and obesity: an overview. Expert Rev Clin Pharmacol. 2026;19(4):313-339. PubMed 41785010 · doi:10.1080/17512433.2026.2642415